Ann Liver Transplant.  2023 Nov;3(2):86-93. 10.52604/alt.23.0023.

ADV score is a reliable surrogate biomarker of hepatocellular carcinoma in liver resection and transplantation

• Hwang S
• Jung DH
• Song GW

• KMID: 2560928
• DOI: http://doi.org/10.52604/alt.23.0023

Abstract

A composite score, known as the ADV score, which is calculated by multiplying the levels of α-fetoprotein and des-γ-carboxy prothrombin along with tumor volume, has been demonstrated as an all-encompassing prognostic indicator for hepatocellular carcinoma (HCC) subsequent to hepatic resection and liver transplantation. This ADV score serves as a quantifiable metric that reflects the underlying characteristics of the tumor. This study was designed to validate the prognostic impact of ADV score in patients who underwent hepatic resection or liver transplantation for HCC through a collective review of twelve studies. The role of ADV score in hepatic resection was assessed in eight studies including five single-center studies, two multi-center studies and one international study. The role of ADV score in liver transplantation was assessed in five studies including four single-center studies and one Korea nationwide multi-center study. The culmination of evidence from these twelve investigations affirms the ADV score's role as a comprehensive surrogate biomarker for predicting the prognosis following hepatic resection or liver transplantation in patients diagnosed with HCC. The utilization of the ADV score for prognostic predictions offers a dependable means to inform the management of patients across varying stages of HCC, facilitating the tailoring of individualized postoperative follow-up plans based on the assessed risk of HCC recurrence.

Keyword

Hepatocellular carcinoma; Hepatic resection; Liver transplantation; Prognostic prediction; Microvascular invasion